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The Community-Level Interventions for Pre-eclampsia (CLIP)
cluster randomised trials in Mozambique, Pakistan, and India:
an individual participant-level meta-analysis
Peter von Dadelszen, Zulfiqar A Bhutta, Sumedha Sharma, Jeffrey Bone, Joel Singer, Hubert Wong, Mrutyunjaya B Bellad, Shivaprasad S Goudar,
Tang Lee, Jing Li, Ashalata A Mallapur, Khátia Munguambe, Beth A Payne, Rahat N Qureshi, Charfudin Sacoor, Esperança Sevene, Marianne Vidler,
Laura A Magee, and the CLIP Trials Working Group*

Summary

Background To overcome the three delays in triage, transport and treatment that underlie adverse pregnancy outcomes,
we aimed to reduce all-cause adverse outcomes with community-level interventions targeting women with pregnancy
hypertension in three low-income countries.
Methods In this individual participant-level meta-analysis, we de-identified and pooled data from the CommunityLevel Interventions for Pre-eclampsia (CLIP) cluster randomised controlled trials in Mozambique, Pakistan, and India,
which were run in 2014–17. Consenting pregnant women, aged 12–49 years, were recruited in their homes. Clusters,
defined by local administrative units, were randomly assigned (1:1) to intervention or control groups. The control
groups continued local standard of care. The intervention comprised community engagement and existing community
health worker-led mobile health-supported early detection, initial treatment, and hospital referral of women with
hypertension. For this meta-analysis, as for the original studies, the primary outcome was a composite of maternal or
perinatal outcome (either maternal, fetal, or neonatal death, or severe morbidity for the mother or baby), assessed by
unmasked trial surveillance personnel. For this analysis, we included all consenting participants who were followed up
with completed pregnancies at trial end. We analysed the outcome data with multilevel modelling and present data
with the summary statistic of adjusted odds ratios (ORs) with 95% CIs (fixed effects for maternal age, parity, maternal
education, and random effects for country and cluster). This meta-analysis is registered with PROSPERO,
CRD42018102564.
Findings Overall, 44 clusters (69 330 pregnant women) were randomly assigned to intervention (22 clusters
[36 008 pregnancies]) or control (22 clusters [33 322 pregnancies]) groups. 32 290 (89·7%) pregnancies in the
intervention group and 29 698 (89·1%) in the control group were followed up successfully. Median maternal age of
included women was 26 years (IQR 22–30). In the intervention clusters, 6990 group and 16 691 home-based
community engagement sessions and 138 347 community health worker-led visits to 20 819 (57·8%) of 36 008 women
(of whom 11 095 [53·3%] had a visit every 4 weeks) occurred. Blood pressure and dipstick proteinuria were assessed
per protocol. Few women were eligible for methyldopa for severe hypertension (181 [1%] of 20 819) or intramuscular
magnesium sulfate for pre-eclampsia (198 [1%]), of whom most accepted treatment (162 [89·5%] of 181 for severe
hypertension and 133 [67·2%] of 198 for pre-eclampsia). 1255 (6%) were referred to a comprehensive emergency
obstetric care facility, of whom 864 (82%) accepted the referral. The primary outcome was similar in the intervention
(7871 [24%] of 32 290 pregnancies) and control clusters (6516 [22%] of 29 698; adjusted OR 1·17, 95% CI 0·90–1·51;
p=0·24). No intervention-related serious adverse events occurred, and few adverse effects occurred after in-community
treatment with methyldopa (one [2%] of 51; India only) and none occurred after in-community treatment with
magnesium sulfate or during transport to facility.
Interpretation The CLIP intervention did not reduce adverse pregnancy outcomes. Future community-level
interventions should expand the community health worker workforce, assess general (rather than condition-specific)
messaging, and include health system strengthening.
Funding University of British Columbia, a grantee of the Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Pregnancy hypertension (ie, all hypertensive disorders of
pregnancy, including chronic hypertension, gestational
hypertension, and pre-eclampsia) complicates appro
ximately 10% of pregnancies in low-income and
www.thelancet.com Vol 396 August 22, 2020

middle-income countries.1 Pre-eclampsia, the form of
pregnancy hypertension associated with proteinuria or
end-organ complications, or both, is associated with the
greatest risk of maternal, fetal, and neonatal mortality and
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Research in context
Evidence before this study
We identified evidence from randomised controlled trials of the
benefit of community mobilisation, task-sharing, and use of
magnesium sulfate to improve pregnancy outcomes, and
evidence from observational studies of the use of methyldopa in
initial management of hypertensive emergencies in volumerestricted patients (eg, women with pre-eclampsia).
The individual country Community-Level Interventions for
Pre-eclampsia (CLIP) trials were done in India, Pakistan, and
Mozambique between 2014 and 2017 to investigate pregnancy
hypertension focused and solely community-level community
engagement, antenatal assessment, risk stratification, initiation
of life-saving therapies, and transport to hospital.
Added value of this study
The CLIP trials are the first to run a solely community-level
intervention for pregnancy hypertension, designed to address the
so-called three delays: triage, transport, and treatment.
The existing community health workforce was scaled up to
provide community engagement and community health workerled app-guided triage, treatment, and transport to a facility for
women with pregnancy hypertension. Overall, the CLIP
intervention did not improve the primary composite of maternal,
fetal, and newborn mortality and morbidity. Community health

For full list of feasibility studies
completed see https://pre-empt.
bcchr.ca/media/publications
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morbidity.2 Globally, pre-eclampsia is the second leading
cause of direct maternal mortality, resulting in an
estimated 76 000 maternal deaths and 500 000 fetal and
newborn deaths every year.3 More than 99% of these deaths
occur in low-income and middle-income countries,
primarily in south Asia and sub-Saharan Africa.4
Generally, research in this field has focused on
institutional-level interventions with magnesium sulfate
(for eclampsia prevention and treatment) and paren
teral antihypertensive therapy for severe hypertension.4
However, many women die or are irreversibly affected by
pre-eclampsia because they never reach an inpatient
facility, either because they die at home or on the way to a
facility, or because they are already in a critical condition
on arrival. As such, the concern is that if research
continues to be restricted to inpatient, facility-level
interventions, maternal lives will be lost due to preeclampsia and eclampsia from delays in triage, transport,
and treatment (ie, the so-called three delays).5 A solution
to these delays might be to provide care to women in
their communities.
The Community-Level Interventions for Pre-eclampsia
(CLIP) study (NCT01911494) comprised three cluster
randomised controlled trials that aimed to reduce the
burden of adverse maternal and perinatal outcomes
related to pregnancy hypertension by addressing the
three delays via community-level intervention. Trial
design was informed by extensive feasibility studies
between 2011 and 2014 with pregnant women, mothers,
household proxy decision makers, health-care workers,

workers were able to undertake all aspects of the app-guided
visits, and approximately 10% of pregnant women were found to
be hypertensive using a device validated for use in pregnancy;
however, few women were eligible for in-community treatment,
and the numbers of community health workers were
inadequate to reach all women who could have benefited.
An increased number of app-guided visits was associated with
improved outcomes, with substantial improvements from
eight such contacts.
Implications of all the available evidence
Our findings suggest that community-level interventions
addressing triage, initial treatment, and transport of women
with pregnancy hypertension can be successfully completed by
community health workers, but their numbers must be
adequate to provide at least eight antenatal care contacts to
reduce adverse outcomes. A focus on community-level
intervention without facility enhancement is unlikely to yield
the improvements in maternal and perinatal outcome as hoped
or needed by the global health community. Further studies
should assess a more comprehensive health strategy that
involves facility strengthening and community-level activities
restricted to accurate measurement of blood pressure and
simple condition-specific interventions.

traditional birth attendants and faith-based caregivers,
community and opinion leaders, and health adminis
trators. Literature and document reviews and qualitative,
quantitative, and participatory methods were used to
explore the societal context; acceptability of the inter
vention to women, community health workers (who
delivered it), and health-care providers (who provided
support, as required); government stakeholders (who
would support imple
mentation); and facility assess
ment of staff and resources (including commodities).
Each of the three CLIP trials in India, Pakistan, and
Mozambique, which were completed, was indepen
dently powered and designed a priori to contribute to
an individual participant-level data meta-analysis that
would improve power for assessment of maternal
mortality or morbidity, and other components of the
composite maternal and perinatal primary outcomes of
the CLIP trials.6–9

Methods

Study design
This individual participant-level meta-analysis included
data from the CLIP cluster randomised controlled trials
in India (run from November, 2014, to October, 2016),
Pakistan (January, 2015, to December, 2016), and
Mozambique (February, 2015, to February, 2017)7–9 as
agreed by all CLIP principal investigators (ZAB, MBB,
SSG, AAM, KM, RNQ, CS, ES) and detailed in the CLIP
trial protocol. The included trials were cluster randomised
controlled trials with 12 (India and Mozambique) or
www.thelancet.com Vol 396 August 22, 2020
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20 clusters (Pakistan) comprising complex health system
interventions.
The Individual Patient Data (IPD) proposal was prospec
tively registered with PROSPERO, CRD42018102564, as
were the individual CLIP trials (NCT01911494; the protocol
is in the appendix [pp 12–120]). Ethical approval for the
trials and individual participant-level data meta-analysis
was granted by the University of British Columbia,
Vancouver, BC, Canada (H12-03497) and each country’s
relevant research ethics board (Aga Khan University,
Pakistan, 2590-Obs-ERC-13; KLE University, India, MDC/
IECHSR/2011-12/A-4, ICMR 5/7/859/12-RHN; and Centro
de Investigação em Saúde da Manhiça [CIBS-CISM/038/14],
Mozambique National Bioethic Committee [219/CNBS/14]).
All eligible pregnant women provided written informed
consent to participate.

Study procedures
The units of randomisation (clusters) in India were
primary health centres, in Pakistan were Union Councils
(in Pakistan, provinces are divided into divisions, sub
divisions [tehsil], and thereafter into Union Councils,
comprising a large village and surrounding areas, often
including nearby small villages) and all associated primary
health centres, and in Mozambique were Administrative
Posts (in Mozambique, provinces are divided into districts,
which are further divided into Administrative Posts). Local
teams chose potential clusters according to similar healthcare infrastructure, accessibility for the surveillance team,
and the absence of conflicting concurrent research acti
vity. In India and Pakistan, internal pilot trials (each in an
initial four clusters per country) preceded definitive trials.
Pregnant women aged 15–49 years (12–49 years in
Mozambique) were identified in their homes or local
primary health centres by trained community health
workers. Clusters were randomly assigned (1:1), via
restricted, stratified randomisation according to popu
lation size, to either the intervention or control group. The
trials were unmasked given the nature of the intervention.
Partici
pants in control clusters continued current local
practice around antenatal care, referral to facilities, and
initiation of therapy. The intervention aimed to address the
so-called three delays in triage, transport, and treatment
related to maternal mortality risk. The first step was
community engagement involving women and their
mothers, household male decision makers, mothersin-law, and community leaders regarding pre-eclampsia
awareness and education about birth preparedness
and compli
cation readiness, supported by culturally
appropriate pictograms. Community group meetings were
held in all countries, with additional one-on-one healthcare worker-led meetings in women’s homes in clusters in
Pakistan. In the second step, community health workers
were trained to task-share pregnancy-hypertensionoriented care at CLIP visits in women’s homes, using the
CLIP Pre-eclampsia Integrated Estimate of Risk (PIERS)On-the-Move (POM) mHealth app for risk stratification.10
www.thelancet.com Vol 396 August 22, 2020

The team of community health workers already in place
was trained to make the intervention scalable, if found to
improve outcomes in a trial setting.5 Community health
workers responded to emergency conditions (aided by
country-specific picto
grams), took women’s blood pres
sure using the Microlife BP 3AS1-2 device (Widnau,
Switzerland) and assessed dipstick proteinuria at the first
contact and any subsequent contact when hypertension
was detected. Per-protocol, the minimum number of CLIP
visits should have been at least every 4 weeks, with
additional visits recommended at days 3, 7, and 14 after
birth. Community health workers were directed by the
POM app to either administer oral methyldopa 750 mg for
blood pressure of 160/110 mm Hg or higher; administer
intramuscular magnesium sulfate 10 g for suspected
severe pre-eclampsia (miniPIERS11 risk for an adverse
maternal outcome of at least 25%, severe systolic
hypertension [at least 160 mm Hg], eclampsia, stroke, or
vaginal bleeding); or refer the woman to a comprehensive
emergency obstetric care facility for suspected preeclampsia or increased risk of stillbirth (4+ dipstick
proteinuria value, or absent fetal movements for at least
12 h). In referral facilities shared by both intervention and
control groups, evidence-based care was promoted through
a small number of continuous professional development
events (three in India, three in Pakistan, and six in
Mozambique) spaced throughout the trial periods that
focused on the WHO’s recommendations for prevention
and treatment of pre-eclampsia and eclamspia.12
In intervention and control clusters, surveillance teams
were trained to do regular cross-sectional surveys of
households (every 3–6 months), except in India, where a
prospective population-based surveillance system was
established. After individual participant consent was
obtained, data were collected on baseline individual-level
and household-level information, antenatal care, and
adverse maternal, fetal, and neonatal outcomes up to
6 weeks after birth (for the mother) or 28 days after birth
(for the neonate). Women were defined as withdrawing
from the trial if they declined further trial surveillance.
Women were lost to follow-up if they were more than
6 weeks post partum (based on estimated delivery date) and
more than one surveillance cycle from trial end. Women
were defined as still on follow-up if they either had not
delivered their baby or were post partum within 6 weeks of
their estimated delivery date and within one surveillance
cycle from the trial end. Overall coordination and data
management was done by the Pre-eclampsia – Eclampsia
Monitoring, Prevention and Treatment research group at
The University of British Columbia.7–9

Data analysis
We assessed the risk of bias of each trial according to the
five criteria for cluster randomised controlled trials in the
Cochrane Handbook: recruitment bias, baseline imbal
ance, loss of clusters, incorrect analysis, and comparability
with individualised randomised trials.13
555
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Within Research Electronic Data Capture (REDCap;
version 5, Vanderbilt University, Nashville, TN, USA) we
extracted data, by trial group, for characteristics of: the
trial, women enrolled, and the intervention, and outcomes.
For this meta-analysis, as for the individual trials, the
primary outcome was one or more of the maternal

or perinatal mortality or morbidity outcomes, and
the secondary outcomes were birth preparedness and
complication readiness, the proportion of births that
occurred in a facility, and delivery in a facility that is able to
provide comprehensive emergency obstetric care (panel).
Secondary outcomes included components of the primary

Panel: Outcome definitions for Community-Level Interventions for Pre-eclampsia trials and this meta-analysis
Primary outcome
The primary outcome is a combined maternal or perinatal
outcome (either maternal, fetal, or neonatal death, or severe
morbidity for the mother or baby).
Maternal outcomes
Maternal death was defined as the number of deaths during
pregnancy or within 42 days of pregnancy (or last contact day
if contact was not maintained to 42 days) per 1000 identified
pregnancies, defined as the maternal death rate.
Maternal morbidity was defined as the number of women with
one or more life-threatening complication of pregnancy during
pregnancy or within 42 days of pregnancy or last contact day
if contact was not maintained to 42 day, per 1000 identified
pregnancies. Complications of pre-eclampsia were defined as
follows:
Serious end-organ complications of pre-eclampsia
• Eclampsia: occurrence of generalised convulsions during
pregnancy, labour, or within 42 days of delivery in the
absence of epilepsy or another condition predisposing to
convulsions
• Stroke: hemiparesis, blindness, or both, developed during
pregnancy or in the 42 days post partum, lasting longer
than 48 h
• Coma: unconsciousness for ≥12 h
• Antepartum haemorrhage: vaginal bleeding of ≥15 mL with
or without pain before the onset of labour
• Disseminated intravascular coagulation: abnormal bleeding
from mucosa (mouth, ears, or both)
Other major causes of maternal mortality
• Obstetric sepsis: in the community, defined as fever and
one of abdominal or uterine tenderness, foul smelling vaginal
discharge or lochia, productive cough and shortness of
breath, dysuria or flank pain, or headache and neck stiffness
• Vesicovaginal or rectovaginal fistula: continuous loss of
urine, faeces, or both, after delivery
Life-saving interventions
• Cardiopulmonary resuscitation: a set of emergency
procedures including chest compressions and lung
ventilation applied in cardiac arrest victims
• Dialysis: haemodialysis, peritoneal dialysis, or both
• Mechanical ventilation (other than for caesarean section):
intubation and ventilation not related to anaesthesia
• Blood transfusion: one or more units of blood product
• Interventions for major post-partum haemorrhage:
brace sutures, external and internal uterine compression,
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antishock garment use, internal iliac artery ligation,
or hysterectomy with or without transfusion
Perinatal outcomes
Perinatal and late neonatal death was defined as stillbirth
(gestational age ≥20 weeks, ≥500 g, or both), early neonatal
mortality (within 0–7 days of birth) and late neonatal
mortality (within 8–28 days of birth) per 1000 identified
pregnancies.
Neonatal morbidity was defined as occurrence of a primary
neonatal morbidity during 0–28 days of birth per
1000 identified pregnancies. Primary neonatal morbidities
were:
• Feeding difficulty: including inability to suckle normally or
latch on to the mother’s breast to feed even if the mother’s
milk is not let down
• Breathing difficulty: including grunting and in-drawing of
the abdomen under the ribs
• Seizure: occurrence of any seizure event (fits)
• Lethargy: baby not appearing normally wakeful after
activities such as feeding or sleeping
• Coma: a non-medically induced period of unconsciousness
of any length
• Hypothermia: baby is cold to touch
• Umbilical cord infection: characterised by discharge from
and redness around the umbilical stump
• Skin infection: any appearance of abnormally red, black,
swollen, or blistered skin with pus
• Bleeding from anywhere on the body
• Jaundice: yellow skin and eyes
• CNS-related morbidity: abnormal amount of vomiting as
defined by the parents or caregiver with bulging or sunken
fontanelle
Secondary outcomes
Birth preparedness and complications readiness: defined as
having completed three or more of arranging for transport,
obtaining prior permission for transport, saving money for
obstetric care, identifying a skilled birth attendant, and
identifying a facility for birth.
In-facility birth, defined as any birth at a health-care facility.
Birth at a comprehensive emergency obstetric care facility,
defined as birth at any centre that provides basic functions and
capability of doing a caesarean section, giving safe blood
transfusions, and provision of care for sick and
low-birthweight neonates, including resuscitation.

www.thelancet.com Vol 396 August 22, 2020
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outcome (including a composite of maternal mortality or
morbidity, and a composite of stillbirth, neonatal death, or
neonatal morbidity) and safety outcomes. Adverse events
that we assessed were transport-related injury or death
and infection-site haematoma or infection after intra
muscular magnesium sulfate in the community. In India
(given trial surveillance informed by facility data), we also
included as part of this meta-analysis maternal systolic
blood pressure of below 110 mm Hg on arrival at a facility
after in-community methyldopa; respiratory depression,
coma, or death during transport after in-community
magnesium sulfate; and infection-site haematoma or
infection after intramuscular magnesium sulfate incommunity or at a facility. We were unable to follow up the
details of a woman’s management and clinical courses
after she was referred to facility. Serious adverse events
were defined as being serious, unexpected (in nature,
severity, or frequency), and thought to be related to the
study intervention.
For the primary individual participant-level data metaanalysis, we included all CLIP participants who were
followed up with regards to the primary outcome of this
meta-analysis. However, women who withdrew, were lost
to follow-up, or still on follow-up at trial end were included
in a sensitivity analysis in which we used the imputation
from the primary trials in the individual participant-level
data meta-analysis. Each trial was independent, no
potential overlap existed between enrolled participants.
With a planned sample size of approximately
60 600 women in 44 clusters, we would have 80% power
to find a 20% reduction in the composite maternal and
perinatal outcome, from a baseline of 10·2% and with
an intraclass correlation coefficient (ICC) of 0·006.
Furthermore, this sample size would give similar power
to find a 20% reduction in maternal mortality or
morbidity if the baseline rate were 1·7% and the ICC
were less than 0·001 (appendix pp 122–54). A 20% reduc
tion was chosen a priori as being clinically relevant by
consensus within the CLIP group of experts and the
research programme technical advisory group.
We combined data from each trial dataset by study
group. We summarised data as median (IQR) for con
tinuous variables and n (%) for categorical variables. While
in the primary trials we imputed outcomes for women
with incomplete data, in this meta-analysis we only include
data from women with complete follow-up.7–9 We assessed
the treatment effect on the various outcomes using
generalised mixed-effect models with random effects for
both country and cluster, and fixed effects for the study
group and baseline characteristics of maternal age, basic
education, previous pregnancy (parity), and neonatal
mortality rate from each country’s baseline survey as part
of the feasibility studies. We used a one-stage approach, in
which a single model is fitted directly using the results
from each study, to make optimal use of data.14 The
summary statistic was the adjusted odds ratio (OR; fixed
effect for maternal age, parity [nulliparous vs parous], and
www.thelancet.com Vol 396 August 22, 2020

maternal education, and random effects for country and
cluster) with Wald-type 95% CI. We assessed between-trial
heterogeneity using the τ² (estimated as the variance term
of the random effect for treatment in the mixed-effect
model) and R² statistics (as the ratio of the SEs of the
treatment effect from a model with fixed slope and a model
with a random slope).15 A τ² close to 0 and R² close to 1
were taken as indicating a lack of heterogeneity. Statistical
significance (two-sided) was set at a p value of less than
0·05 for the composite maternal and perinatal outcome,
and a p value of less than 0·001 for other analyses.
We did four types of sensitivity analyses for the primary
outcome and its components to assess the effect of potential
sources of bias on our results. First, women who were
defined as lost to follow-up or still on follow-up at the end
of the trial were included to assess the potential effect of
missingness. As for the primary analysis of the individual
CLIP trials, mixed imputation was used to account for the
risk associated with each woman, depending on her
personal baseline characteristics, cluster characteristics,
and time of enrolment relative to the beginning of the trial.
Second, we restricted the adjusted analysis to women
whose pregnancies continued to at least 20 weeks, because
the average gestational age at recruitment was much earlier
in India (approximately 11 weeks) than in Pakistan (approxi
mately 21 weeks) and Mozambique (approxi
mately
26 weeks).7–9 As for the individual CLIP trials and according
to the statistical analysis plan (appendix pp 122–54),
inclusion for this sensitivity analysis was: restricted to
women who had 42 days of post-partum follow-up data;
restricted to women with anticipated birth (according to
estimated delivery date) or anticipated birth and 42 day of
post-partum follow-up data within the trial timeline, to
assess the effect of the intervention independent of
gestational age at birth; and expanded to include women
who were enrolled into trial surveillance only post partum,
which might have reflected an effect of community
engagement but was a protocol deviation. Third, we did an
unadjusted analysis without accounting for baseline
individual-level and cluster-level characteristics. Fourth, we
did a so-called on-treatment analysis of women who
received at least one community health worker-led POMguided visit in intervention versus control clusters.
In an additional planned secondary analysis, we explored
in the intervention group whether an association existed
between our primary outcome and the number of CLIP
visits, measured as 0, 1–3, 4–7, or 8 or more visits, to reflect
previous and current WHO recommendations for the
frequency of antenatal care contacts.16 To account for
factors related to the number of POM-guided visits and
confounders, the analysis was restricted to women whose
pregnancies continued beyond 20 weeks and was adjusted
for maternal age, basic education, parity, time of enrol
ment in the trial, and distance from the household to a
facility.
We used R statistical software (version 3.5.2) for all
analyses.
557
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Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had full access to
all data in the study and final responsibility for the
decision to submit for publication.

Results
The general characteristics of the CLIP trials, their
participants, intervention implementation, and outcomes
are presented in the appendix (pp 4–5).
In the three CLIP trials, comprising 44 clusters
(n=22 intervention, n=22 control), 69 330 participants
were enrolled (36 008 pregnancies in the intervention
group and 33 322 in the control group), some of whom
were pregnant more than once, such that we had a
third more births than expected per cluster (appendix
pp 11–121). 61 988 (89·4%) pregnancies were successfully
followed up (32 290 [89·7%] in the intervention group
and 29 698 [89·1%] in the control group), at similar and
high rates across countries (appendix pp 4–5). Few
women withdrew from the study (four [<0·1%] in the
intervention group and five [<0·1%] in the control
group). Loss to follow-up, which only occurred in
Pakistan and Mozambique, was slightly lower (by 0·7%)
in intervention clusters; loss to follow-up was attributed
to migration and cyclical surveillance cycles by study
site staff. Just under 8% of pregnancies (2811 [7·8%] in
the intervention group and 2555 [7·7%] in the control
group) were ongoing and still on follow-up on the trial
end date.
The median maternal age of included women was
26 years (IQR 22–30) across all countries (appendix
pp 4–5). Basic education, as measured by each country,
had been received by over 60% of women in India (ie, at
least 8 years of schooling) and Mozambique (ie, at least
grade 5), but by no more than 20% in Pakistan (ie, at least
5 years of schooling). Overall, over 70% of women in all
countries were parous. The median gestational age at
trial enrolment was 19·0 weeks (IQR 12·5–26·8), with
the earliest in India (approximately 11 weeks), followed
by Pakistan (approximately 21 weeks) and Mozambique
(approximately 27 weeks).
23 681 (6990 group and 16 691 home-based) community
engagement sessions were held by the CLIP country
teams (appendix pp 4–5). Training (of 2–15 days’ duration)
was delivered to 450 health-care providers, with refresher
training every 1–6 months. Methyldopa and magnesium
sulfate were sourced in-country. Trained community
health workers provided 138 347 visits for a median of
six visits per pregnancy, four (IQR two to six) antenatal
and two (IQR one to three) post partum. 20 819 (57·8%) of
36 008 women in the intervention group had one or more
POM-guided visits, approximately half of whom had
visits that were compliant with the minimum frequency
(11 095 [53·3%] of 20 819). Blood pressure was measured
at almost all visits (137 705 [99·5%]), and dipstick
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proteinuria was done at 21 257 [96·4%] of 22 051 relevant
visits as per the protocol (ie, first and all subsequent visits
at which hypertension was detected). POM-guided
visits resulted in recommendations at 136 755 (98·9%)
visits. As previously published, hypertension was iden
tified in 2111 [9·9%] of 21 306 pregnancies (636 [10·3%] of
6149 in India; 1010 [9·3%] of 10 904 in Pakistan;
and 465 [10·9%] of 4253 in Mozambique).1 181 (0·9%) of
20 819 women were eligible for treatment with oral
methyldopa for severe hypertension and 198 (1·0%) were
eligible for intramuscular magnesium sulfate for preeclampsia, and 1255 (6·0%) women were referred to a
facility. Most women accepted the community health
workers’ POM-guided recommendations to administer
oral methyldopa (162 [89·5%] of 181 eligible pregnancies)
and intramuscular magnesium sulfate (133 [67·2%] of
198), and referral to a comprehensive emergency obstetric
care facility (864 [81·6%] of 1255 pregnancies with recom
mended referral).
Protocol deviations occurred in few pregnancies
(295 [0·9%] of 32 290) in the intervention group, of
which 46 (15·6%) were related to treatment or referral
not recommended as per the POM app and protocol
(n=40 in India, n=4 in Pakistan, and n=2 in Mozambique)
and 249 (84·4%) were antenatal CLIP visits by the
community health workers among women only enrolled
by the trial surveillance team during their post-partum
period (n=6 in India, n=23 in Pakistan, and n=220 in
Mozambique); pregnancies that had protocol deviations
did not result in withdrawals or adverse events.
No effect of the CLIP intervention was seen on the
primary composite maternal and perinatal outcome
(7871 [24·4%] pregnancies in intervention group had
one or more of the predefined maternal or perinatal
mortality or morbidity outcomes vs 6516 [21·9%]
pregnancies in the control group; adjusted OR 1·17,
95% CI 0·90–1·51) or its components, as was the case in
each included cluster randomised controlled trial
(table 1, figure).7–9 Most events were morbidities for the
mother (6062 [9·8%] of 61 998 pregnancies) and neonate
(6299 [10·2%]). Death was rare for mothers (143 [0·2%]),
but not so for fetuses and neonates, with similar rates of
stillbirth (2591 [4·2%]) and neonatal death (2677 [4·3%]).
The ICC was 0.059. Similar patterns were seen across
countries (appendix pp 4–5). The intervention had no
effect on secondary outcomes (table 1). Approximately
half of women in both groups showed birth preparedness
and complication readiness. Most women delivered in
a facility, with approximately half of women overall
delivering in a comprehensive emergency obstetric care
facility. We found no evidence of between-trial hetero
geneity in outcomes. The gestational age at delivery was
39 weeks (IQR 37–41) for both intervention and control
clusters.
No serious adverse events related to the intervention
or study occurred (appendix p 5) and few adverse events
occurred. In one (2·0%) of 51 women in the intervention
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Event rate
Intervention clusters
(n=32 290 women)
Primary composite maternal and
perinatal outcome†
Maternal outcome

Adjusted odds
ratio*

p value

τ²

R²

Control clusters
(n=29 698 women)

7871 (24·4%)

6516 (21·9%)

1·17 (0·90–1·51)

0·24

0·007

1·08

3369 (10·4%)

2781 (9·4%)

1·20 (0·84–1·74)

0·32

0·003

1·01

66 (0·2%)

1·05 (0·67–1·64)

0·84

0·002

1·24

Maternal mortality

77 (0·2%)

Maternal morbidity

3319 (10·3%)

2743 (9·2%)

1·20 (0·83–1·74)

0·32

0·003

1·00

5618 (17·4%)

4760 (16·0%)

1·10 (0·89–1·37)

0·38

0·003

1·06

Stillbirth

1322 (4·1%)

1269 (4·3%)

1·03 (0·89–1·19)

0·69

0·003

1·00

Neonatal mortality

1408 (4·4%)

1269 (4·3%)

1·10 (0·96–1·27)

0·17

0·005

1·44

Neonatal morbidity

3463 (10·7%)

2836 (9·5%)

1·09 (0·73–1·62)

0·69

0·025

1·12

15 875 (53·4%)

13 530 (45·5%)

0·91 (0·41–2·02)

0·82

0·001

1·01

Perinatal mortality, late neonatal
death, or neonatal morbidity

Secondary outcomes
Birth preparedness and
complication readiness‡
Proportion of facility births

25 397 (85·5%)

23 282 (78·7%)

1·06 (0·82–1·36)

0·66

0·01

1·13

Birth at a comprehensive
emergency obstetric care
facility

14 657 (49·3%)

14 398 (48·5%)

0·84 (0·59–1·19)

0·32

0·001

1·01

Data are n (%) or adjusted odds ratio with 95% CI in parentheses, unless otherwise stated. τ² is estimated as the variance term of the random effect for treatment in the mixed
effect model and R² is the ratio of the SEs of the treatment effect from a model with fixed slope and one with a random slope. CLIP=Community-Level Interventions for
Pre-eclampsia. *Adjusted for maternal age, parity, and maternal basic education. †Defined as one or more of maternal morbidity or mortality, stillbirth, neonatal mortality,
or neonatal morbidity; the primary outcome in the CLIP trials. ‡Birth preparedness was defined as a “Yes” answer to all of the following: arranged for transport, obtained prior
permission to seek emergency care, and saved money for obstetric care.

Table 1: Primary and secondary outcomes

group in India, in-community receipt of methyldopa was
associated with a decrease in blood pressure from a
median of 167/108 mm Hg (IQR 162/100 to 178/113) to
160/100 mm Hg (146/90 to 170/110) after a median of
97 min (75–150). Injection-site haematoma or infection
was reported only after receipt of magnesium sulfate infacility (four [2·4%] of 168 in intervention group vs
1386 [3·5%] of 26 698 in the control group, in India only)
and none was reported after in-community administra
tion. No injuries related to transport to facility occurred.
Recruitment bias was regarded as low in all included
trials. Although participants and their care providers were
aware of their assignment to intervention or control
clusters in this complex health system intervention study,
enrolment in the trials was based on household residence.
Clusters were defined by the unit of the primary healthcare system associated with a woman’s household;
therefore, she could not simply choose to participate
in another study area. Enrolment was slightly higher
(by 8·7%), and loss to follow-up lower (by 0·7%) in
intervention clusters than in control clusters (p<0·0001),
which could cause concern about the risk of bias
associated with baseline imbalances in the clusters. In
India, one cluster was replaced by another with similar
characteristics early in the pilot phase, and clearly before
data analysis, in response to issues with primary health
centre leadership and data integrity; otherwise, there
were no concerns related to loss of clusters, incorrect
analysis, or variability between clusters (because each
www.thelancet.com Vol 396 August 22, 2020

Stillbirth and neonatal outcomes
Maternal outcomes
Composite outcomes
Country
Pakistan
Mozambique
India
Overall
0·75

1·00

1·25

1·50

1·75

2·00

Favours intervention Favours control
Adjusted odds ratio

Figure: Forest plot of primary composite outcome and its components in
each CLIP trial and overall
Data points are adjusted odds ratios with 95% CIs indicated with whiskers.
CLIP=Community-Level Interventions for Pre-eclampsia.

trial accounted for clustering and reported ICC for each
outcome).
In sensitivity analyses, the CLIP intervention had no
effect when data for women defined as lost to or still
on follow-up were imputed, unadjusted for baseline
maternal characteristics, restricted to women whose
pregnancies continued to at least 20 weeks, or in our
on-treatment analysis restricted to women who received
at least one community health worker-led POM-guided
visit (adjusted OR 1·12, 95% CI 0·86–1·47, p=0·40;
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0 visits

1–3 visits

4–7 visits

Adjusted
odds ratio†

Event rate
(n=4309)

Primary outcome‡ 2928 (27·2%)

1 (ref)

1251 (29·0%)

1·07 (0·98–1·18)

0·16

2340 (26·1%)

Maternal outcome 1246 (11·6%)

1 (ref)

539 (12·5%)

0·96 (0.84–1·08)

0·49

1040 (11·6%)

Event rate
(n=10 754)

Adjusted odds
ratio†

p value

Event rate
(n=8974)

≥8 visits
Adjusted odds
ratio†

p value

Event rate
(n=6684)

Adjusted odds
ratio†

p value

0·95 (0·88–1·03)

0·21

1242 (18·6%)

0·88 (0·80–0·97)

0·0079

0·92 (0·82–1·02)

0·11

436 (6·5%)

0·86 (0·74–0·99)

0·032

Maternal
mortality

24 (0·2%)

1 (ref)

11 (0·3%)

0·96 (0·42–2·18)

0·92

14 (0·2%)

0·57 (0·28–1·19)

0·14

5 (0·1%)

0·32 (0·11–0·92)

0·035

Maternal
morbidity

1229 (11·5%)

1 (ref)

535 (12·4%)

0·97 (0·86–1·10)

0·63

1032 (11·5%)

0·93 (0·83–1·03)

0·16

435 (6·5%)

0·87 (0·76–1·01)

0·060

2132 (19·9%) 1 (ref)

922 (21·5%)

1·16 (1·05–1·28)

0·0047

1634 (18·2%)

0·96 (0·88–1·05)

0·37

928 (13·9%)

0·86 (0·77–0·95)

0·0037

Fetal or neonatal
adverse outcome
Stillbirth

505 (4·7%)

1 (ref)

279 (6·5%)

1·54 (1·30–1·81)

<0·0001

396 (4·4%)

0·88 (0·76–1.02)

0·098

142 (2·1%)

0·41 (0·33–0·51)

<0·0001

Neonatal
mortality

545 (5·3%)

1 (ref)

260 (6·5%)

1·34 (1·14–1·58)

0·0005

414 (4·8%)

0·93 (0·81–1·08)

0·35

188 (2·9%)

0·66 (0·54–0·81)

<0·0001

Neonatal
morbidity

1266 (11·8%)

1 (ref)

485 (11·3%)

0·87 (0·76–0·99)

0·034

986 (11·0%)

0·99 (0·89–1·10)

0·79

725 (10·9%)

1·24 (1·09–1·41)

0·0016

Data are number of events and proportion of total events by visit number category, and adjusted odds ratio with 95% CI in parentheses, unless otherwise stated. CLIP=Community-Level Interventions for
Pre-eclampsia. POM=Pre-eclampsia integrated estimate of risk-On-the-Move. *These analyses included the 30 721 women in intervention clusters who were followed-up, excluding the 1341 women who were
followed-up (ie, excluding 1341 women from the total population who were recruited and had a miscarriage before 20 weeks). †Adjusted for maternal characteristics (as in the primary analysis: maternal age,
parity, basic education, and gestational age at enrolment; enrolment timing in the trial; and distance from the household to facility. ‡Defined as one or more of maternal morbidity or mortality, stillbirth,
neonatal mortality, or neonatal morbidity; the primary outcome in the CLIP Trials.

Table 2: Sensitivity analysis of the association between number of community health-care worker POM-guided CLIP visits and the primary outcome among 30 721 pregnancies in CLIP*

appendix p 6). However, there was an association
between number of visits and outcomes (table 2). Fewer
women with eight or more CLIP visits had a CLIP
primary outcome or its components than those with
no visits, an effect that was seen in each of the three
countries (table 2; appendix p 8). The exception was
neonatal morbidity, which was increased among those
with eight or more visits (vs no visits) and not associated
with a difference in gestational age at delivery (median
39 weeks in both intervention and control clusters;
appendix p 9). Women with four to seven visits had an
incidence of outcomes that were intermediate between
those with eight or more visits and those with one to
three visits. However, women with one to three visits
had more adverse perinatal outcomes than did women
without a POM-guided visit; we have previously reported
that these women were enrolled 2–4 weeks earlier than
those without a POM-guided visit, but we did not identify
other baseline differences.7–9

Discussion
The three CLIP cluster randomised controlled trials in
India, Pakistan, and Mozambique involved just over
60 000 pregnancies in 44 clusters. 23 681 community
engagement sessions were run, in groups in all countries
and one-on-one with women and their immediate
community in Pakistan. Community health workers
proficiently carried out POM-guided visits for pregnant
women in their communities, successfully measuring
blood pressure and proteinuria, and providing POM appguided triage and initial treatment of severe hypertension
(with methyldopa) and suspected severe pre-eclampsia
(with magnesium sulfate). Nevertheless, our communitylevel intervention for pregnancy hypertension had no
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effect on a composite of all-cause maternal and perinatal
mortality or morbidity compared with care as usual, as
observed in the individual country-level trials.7–9
Our findings are unlikely to be related to low statistical
power, despite our higher than anticipated ICC (ie, 0·059
vs 0·006 anticipated). The event rate (14 387 [23·2%] of
61 988 pregnancies) was higher than anticipated (10·2%),
as it was for the combined maternal outcome of maternal
mortality and morbidity (ie, 6150 [9·9%] of pregnancies vs
1·7% anticipated). Also, the 95% CI of the adjusted OR of
the combined outcome and its maternal, fetal, and
neonatal components did not include the 20% reduction
considered a priori to be important.
The CLIP intervention did not reach all women who
could have benefited from it. First, only about two-thirds
of women enrolled in intervention clusters received at
least one CLIP visit, and just over half of these women
had visits at the target frequency of once every 4 weeks.
This limitation in human resource capacity in study
areas came from our decision to use the existing
community health worker workforce for scalability.
However, expansion of this workforce might be
worthwhile given that a higher number of POM-guided
CLIP visits reduced the odds of the composite primary
outcome and its components, other than survivable
neonatal morbidity, which increased. This benefit was
seen with eight or more visits, consistent with the WHO
recommendations for eight antenatal care contacts.16
Second, the POM-guided care algorithm focused on
referrals for systolic hypertension, detected in 1255 visits
(0·9% of 138 347 visits; 6·0% of 20 819 pregnancies).
This approach was taken to direct resources to women at
highest risk of stroke and not overwhelm referral
facilities, and to enable measurement of blood pressure
www.thelancet.com Vol 396 August 22, 2020
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by palpation (using an inflatable cuff) given inadequate
access to accurate and affordable equipment in our study
settings. However, in this young maternal population,
isolated diastolic hypertension predominated (1314 [62%]
of 2111 women with hypertension),1 and the blood pres
sure device used in CLIP has proven to be both usable
and affordable.17 Whether referral of more women with
hypertension to the relevant facilities would have been
possible without overwhelming their scarce resources, or
whether com
munity-level treatment of hypertension
could have improved outcomes is unknown.
Despite the importance of hypertension as a cause
of maternal and perinatal mortality and morbidity,
treatment of severe hypertension and use of magnesium
sulfate for eclampsia prevention were aspects of the
CLIP intervention for which only a small proportion of
women were eligible. Despite the evidence base for
effectiveness and safety of these treatments18,19 and shown
safety in our study settings, the rarity that women were
eligible to receive them makes the likelihood that these
treatments would have had an effect on outcomes overall
is low. Notably, considerable training and permissions for
task-sharing are required for community health workers to
administer intramuscular magnesium sulfate. Although
oral methyldopa for severe hypertension was indicated
for a similarly small proportion of women, adminis
tration was straightforward, which raises the potential
for community-level treatment of low-risk hypertension
(ascertained by miniPIERS risk prediction11) and managed
by a simple antihypertensive algorithm.20 By contrast,
blood pressure measurement, using the Microlife
BP 3AS1-2 device validated for use in pregnancy, showed
that at least 10% of women in our study settings had
pregnancy hypertension that was usually gestational
hypertension without proteinuria, a condition amenable to
enhanced surveillance and timed delivery.1
This individual participant-level meta-analysis is a novel
meta-analysis of trials testing a combination of com
munity engagement and mHealth-supported task-sharing
with community health workers focused on pregnancy
hypertension. In a 2015 Cochrane review of communitybased interventions in pregnancy,21 eight of 26 cluster
randomised controlled trials included studied a package
of community mobilisation and home visits. Six of these
cluster randomised controlled trials were in India or
Pakistan. Three cluster randomised controlled trials
focused on home counselling and education22,23 or home
visits by traditional birth attendants who inquired
about warning symptoms of pregnancy complications.24
However, five cluster randomised controlled trials focused
on newborn interventions25–29 and five focused on
strengthened labour and delivery care, with or without
provision of clean delivery kits.24,25,27–30 Community-based
intervention packages were associated with a nonsignificant decrease in maternal mortality and significant
decreases in maternal morbidity, stillbirth, and neonatal
mortality; neonatal morbidity was not reported.21 The
www.thelancet.com Vol 396 August 22, 2020

decrease in maternal morbidity was driven by results of
one trial in Pakistan where the traditional birth attendants
received clean delivery kits and strengthened the provision
of facility care in the intervention group.24 By contrast, the
CLIP trials used community-level hypertension-focused
antenatal care, with minimal facility-enhanced quality of
care in both intervention and control groups. With regards
to the reduction in stillbirth, two of three trials provided
broad additional antenatal care training to community
health workers who also worked with traditional birth
attendants to enhance the quality of labour and delivery
care.27,28 CLIP focused only on pregnancy hypertensionrelated antenatal care with minimal facility enhancement
in all clusters. Finally, five of six trials that reported
neonatal mortality had newborn care as part of the
intervention.25,27–30 CLIP focused entirely on communitylevel interventions for the mother and fetus, but not for
the neonate.
Strengths of our analysis include the planned metaanalysis and harmonisation of study processes and
outcome definitions; the large size of the trial popula
tions and comprehensive recruitment of almost all
eligible unselected pregnant women to mirror routine
antenatal care; successful implementation of community
health worker-led POM-guided antenatal care visits
oriented around hypertension in women’s community
with regards to reach and fidelity; that the intervention
and outcome assessment were done by different teams;
and the consistency of findings across three countries.
Limitations include potential ascertainment bias, which
cluster randomised controlled trials are susceptible to;
nevertheless, any difference in recruitment and loss to
follow-up in intervention clusters was very small.
Another limitation is our reliance on the existing
community health-care workforce, which affected the
extent to which the intervention could be delivered.
Although designed to reflect the scalability and
sustainability of the intervention, our study has
emphasised that the health systems at our study sites are
currently inadequate to implement a complex, conditionspecific, community-level intervention. A focus on the
community without facility enhancement was an
additional limitation, but we have gathered unique
information about the merits of community-level inter
vention in isolation. We were unable to assess the effect
of the CLIP visit content on outcomes. Strengths of
the CLIP visit content were that blood pressure and
proteinuria were measured at almost all relevant visits
and that community health workers were proficient with
the POM app; however, the number of women who were
eligible to receive oral methyldopa or intramuscular
magnesium sulfate was too small to make an analysis of
acceptance of in-community treatment feasible. A full
process evaluation is planned to explore more compre
hensively the context (including cost), implementation,
and mechanisms of effect of our intervention in each of
the three CLIP countries.31
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For more on the Sustainable
Development Goal 3 see
https://www.un.org/
sustainabledevelopment/health/

Management and detection of pregnancy hypertension
provide a gateway to excellence in maternity care. Ideally
a health system should be able to identify and respond to
pregnancy hypertension, induce labour, and provide
both safe caesarean deliveries and care in the postpartum period. Achievement of these markers of good
quality maternity care would contribute substantially to
achievement of Sustainable Development Goal 3.1.
In summary, our findings suggest that communitylevel intervention addressing triage, initial treatment,
and transport of women with pregnancy hypertension
can be successfully implemented by community health
workers, but their numbers must be adequate to provide
at least eight antenatal care contacts to reduce adverse
outcomes. Even then, the reduction is not large, sug
gesting that a focus only on community-level inter
vention without facility enhancement is unlikely to yield
the improvements in maternal and perinatal outcome
as hoped or as needed by the global health community.
Further study should include community-level care
restricted to adequate measurement of blood pressure
and simple condition-specific interventions as part of a
comprehensive health-strengthening programme.
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